Vantage Reports
Drawing on Evaluate data, Vantage reports provide an in-depth view on trends in the biotech, pharma and medtech sectors. Our special reports also provide a detailed look at some of the industry's hottest topics.
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and…
Evaluate Vantage 2021 Preview
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
Evaluate Vantage COVID-19 Report
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered…
Evaluate Vantage 2020 Preview
The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
Vantage Pharma, Biotech and Medtech 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for…
Vantage 2019 Preview
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
First-line lung cancer: can Keytruda be stopped?
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…
